Patients suffering from fibromyalgia were hopeful that low-dose naltrexone, an opioid receptor antagonist, would provide them with much-needed pain relief. However, a recent randomized trial dashed those hopes. According to Dr. Karin Due Bruun and colleagues from Odense University Hospital in Denmark, the trial showed that patients assigned to naltrexone experienced a mean decline in
0 Comments
In a recent Senate oversight hearing, Wall Street CEOs expressed their concerns over proposed regulations that would increase the levels of capital banks need to hold against future risks. While their testimonies aimed to raise alarms about the potential negative impact of these changes, it is important to critically analyze their arguments and consider the
0 Comments
In a recent development, Alan Rosa, the former global head of security, information technology, and privacy at Twitter, has filed a lawsuit against X, Elon Musk, and Steve Davis, a company advisor. Rosa alleges that he was wrongfully terminated after raising objections to cost-cutting measures implemented following Musk’s acquisition of the company last year. This
0 Comments
Robert Jenrick, the immigration minister, has recently stepped down from his position due to “strong disagreements” with the government’s Rwanda policy. This decision comes after Rishi Sunak, the Chancellor of the Exchequer, introduced emergency legislation aimed at reviving the stalled asylum plan. However, Jenrick expressed doubts about whether this legislation would effectively address the legal
0 Comments
In a recent study presented at the International Gynecologic Cancer Society’s annual meeting, trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, demonstrated highly encouraging response rates in patients with HER2-expressing gynecologic cancers. Dr. Ritu Salani of the University of California Los Angeles discusses the findings from the DESTINY-PanTumor02 trial and explains why they have the potential to
0 Comments